Dopaminergic function in relation to genes associated with risk for schizophrenia: Translational mutant mouse models

Progress in Brain Research

Volumn 211, Issue , 2014, Pages 79-112

  Moran, Paula M ^a   O'Tuathaigh, Colm M P ^b   Papaleo, Francesco ^c   Waddington, John L ^d  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c Instituto Italiano di Tecnologia   (Italy)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Dopamine; DTNBP1; Dysbindin; Mutant mice; NRG1; Psychosis; Risk genes; Schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; DYSBINDIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NEU DIFFERENTIATION FACTOR; DTNBP1 PROTEIN, MOUSE; DYSTROPHIN ASSOCIATED PROTEIN; NRG1 PROTEIN, MOUSE;

ARTICLE; COGNITION; CYTOLOGY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; ENVIRONMENTAL FACTOR; EPISTASIS; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; LOCOMOTION; MOUSE; MOUSE MUTANT; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DYSTROPHIN-ASSOCIATED PROTEINS; MICE; NEUREGULIN-1; SCHIZOPHRENIA;

EID: 84904609730     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63425-2.00004-0     Document Type: Chapter

References (225)

1. Abazyan B., Nomura J., Kannan G., Ishizuka K., Tamashiro K.L., Nucifora F., et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biol. Psychiatry 2010, 68:1172-1181.
2. Abe Y., Namba H., Zheng Y., Nawa H. In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: implication of ErbB receptors for dopaminergic neurons. Neuroscience 2009, 161:95-110.
3. Alemany S., Arias B., Fatjó-Vilas M., Villa H., Moya J., Ibáñez M.I., et al. Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr. Scand. 2014, 129:54-62.
4. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 2008, 40:827-834.
5. Andersson R.H., Johnston A., Herman P.A., Winzer-Serhan U.H., Karavanova I., Vullhorst D., et al. Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent upon dopamine D4 receptors. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:13118-21313.
6. Arnsten A.F., Cai J.X., Murphy B.L., Goldman-Rakic P.S. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 1994, 116:143-151.
7. Baca M., Allan A.M., Partridge L.D., Wilson M.C. Gene-environment interactions affect long-term depression (LTD) through changes in dopamine receptor affinity in Snap25 deficient mice. Brain Res. 2013, 1532:85-98.
8. Baik J.H. Dopamine signalling in reward related behaviors. Front. Neural Circuits 2013, 7:152. 10.3389/fncir.2013.00152.
9. Bakermans-Kranenburg M.J., van Ijzendoorn M.H. Differential susceptibility to rearing environment depending on dopamine-related genes: new evidence and a meta-analysis. Dev. Psychopathol. 2011, 23:39-52.
10. Barnett J.H., Heron J., Ring S.M., Golding J., Goldman D., Xu K., et al. Gender-specific effects of the catechol-O-methyltransferase Val108/158Met polymorphism on cognitive function in children. Am. J. Psychiatr. 2007, 164:142-149.
11. Bay-Richter C., O'Tuathaigh C.M., O'Sullivan G., Heery D.M., Waddington J.L., Moran P.M. Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action. Int. J. Neuropsychopharmacol. 2009, 12:403-414.
12. Bay-Richter C., O'Callaghan M.J., Mathur N., O'Tuathaigh C.M., Heery D.M., Fone K.C., et al. D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors. Neuropsychopharmacology 2013, 38:1512-1520.
13. Behan A.T., Hryniewiecka M., O'Tuathaigh C.M., Kinsella A., Cannon M., Karayiorgou M., et al. Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways. Neuropsychopharmacology 2012, 37:1773-1783.
14. Benson M.A., Newey S.E., Martin-Rendon E., Hawkes R., Blake D.J. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J. Biol. Chem. 2001, 276:24232-24241.
15. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Brain Res. Rev. 1998, 28:309-369.
16. Berry D., Deater-Deckard K., McCartney K., Wang Z., Petrill S.A. Gene-environment interaction between dopamine receptor D4 7-repeat polymorphism and early maternal sensitivity predicts inattention trajectories across middle childhood. Dev. Psychopathol. 2013, 25:291-306.
17. Bertram I., Bernstein H.G., Lendeckel U., Bukowska A., Dobrowolny H., Keilhoff G., et al. Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Ann. N. Y. Acad. Sci. 2007, 1096:147-156.
18. Bjarnadottir M., Misner D.L., Haverfield-Gross S., Bruun S., Helgason V.G., Stefansson H., et al. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knockouts compared with wild-type mice. J. Neurosci. 2007, 27:4519-4529.
19. Boer S., Berk M., Dean B. Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder. Neurosci. Lett. 2009, 466:27-29.
20. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 1990, 47:181-188.
21. Bray N.J., Preece A., Williams N.M., Moskvina V., Buckland P.R., Owen M.J., et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum. Mol. Genet. 2005, 14:1947-1954.
22. Buonanno A. The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Res. Bull. 2010, 83:122-131.
23. Burdick K.E., Lencz T., Funke B., Finn C.T., Szeszko P.R., Kane J.M., et al. Genetic variation in DTNBP1 influences general cognitive ability. Hum. Mol. Genet. 2006, 15:1563-1568.
24. Burdick K.E., Goldberg T.E., Funke B., Bates J.A., Lencz T., Kucherlapati R., et al. DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr. Res. 2007, 89:169-172.
25. Carr G.V., Jenkins K.A., Weinberger D.R., Papaleo F. Loss of dysbindin-1 in mice impairs reward-based operant learning by increasing impulsive and compulsive behavior. Behav. Brain Res. 2013, 241:173-184.
26. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57:1117-1127.
27. Chen X.W., Feng Y.Q., Hao C.J., Guo X.L., He X., Zhou Z.Y., et al. DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J. Cell Biol. 2008, 181:791-801.
28. Chen Y.J., Johnson M.A., Lieberman M.D., Goodchild R.E., Schobel S., Lewandowski N., et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J. Neurosci. 2008, 28:6872-6883.
29. Chong V.Z., Thompson M., Beltaifa S., Webster M.J., Law A.J., Weickert C.S. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr. Res. 2008, 100:270-280.
30. Collip D., van Winkel R., Peerbooms O., Lataster T., Thewissen T., Lardinois M. COMT Val158Met-stress interaction in psychosis: role of background psychosis risk. CNS Neurosci. Ther. 2011, 17:612-619.
31. Cools R., D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 2011, 69:e113-e125.
32. Corfas G., Roy K., Buxbaum J.D. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat. Neurosci. 2004, 7:575-580.
33. Cox M.M., Tucker A.M., Tang J., Talbot K., Richer D.C., Yeh L., et al. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background. Genes Brain Behav. 2009, 8:390-397.
34. Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee S.H., Ripke S., Neale B.M., Faraone S.V., et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 2013, 45:984-994.
35. Davies G., Tenesa A., Payton A., Yang J., Harris S.E., Liewald D., et al. Genome-wide association studies establish that human intelligence is highly heritable and polygenic. Mol. Psychiatry 2011, 16:996-1005.
36. Deakin I.H., Law A.J., Oliver P.L., Schwab M.H., Nave K.A., Harrison P.J., et al. Behavioural characterization of neuregulin 1 type I overexpressing transgenic mice. Neuroreport 2009, 20:1523-1528.
37. Deakin I.H., Nissen W., Law A.J., Lane T., Kanso R., Schwab M.H., et al. Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation. Cereb. Cortex 2012, 22:1520-1529.
38. Dean B., Karl T., Pavey G., Boer S., Duffy L., et al. Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophr. Res. 2008, 99:341-349.
39. Desbonnet L., O'Tuathaigh C., Clarke G., O'Leary C., Petit E., Clarke N., et al. Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene×environment interaction. Brain Behav. Immun. 2012, 26:660-671.
40. De Steno D.A., Schmauss C. A role for dopamine D2 receptors in reversal learning. Neuroscience 2009, 162:118-127.
41. Dickman D.K., Davis G.W. The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis. Science 2009, 326:1127-1130.
42. Donohoe G., Morris D.W., Clarke S., McGhee K.A., Schwaiger S., Nangle J.M., et al. Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007, 45:454-458.
43. Drew M.R., Simpson E.H., Kellendonk C., Herzberg W.G., Lipatova O., Fairhurst S., et al. Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. J. Neurosci. 2007, 27:7731-7739.
44. Druzin M.Y., Kurzina N.P., Malinina E.P., Kozlov A.P. The effects of local application of D2 selective dopaminergic drugs into the medial prefrontal cortex of rats in a delayed spatial choice task. Behav. Brain Res. 2000, 109:99-111.
45. Duffy L., Cappas E., Scimone A., Schofield P.R., Karl T. Behavioral profile of a heterozygous mutant mouse model for EGF-like domain neuregulin 1. Behav. Neurosci. 2008, 122:748-759.
46. Eda T., Mizuno M., Araki K., Iwakura Y., Namba H., Sotoyama H., et al. Neurobehavioral deficits of epidermal growth factor-overexpressing transgenic mice: impact on dopamine metabolism. Neurosci. Lett. 2013, 547:21-25.
47. Elvevåg B., McCormack T., Gilbert A., Brown G.D., Weinberger D.R., Goldberg T.E. Duration judgements in patients with schizophrenia. Psychol. Med. 2003, 33:1249-1261.
48. Fallgatter A.J., Herrmann M.J., Hohoff C., Ehlis A.C., Jarczok T.A., Freitag C.M., et al. DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals. Neuropsychopharmacology 2006, 31:2002-2010.
49. Falls D.L. Neuregulins and the neuromuscular system: 10 years of answers and questions. J. Neurocytol. 2003, 32:619-647.
50. Fan X., Hess E.J. D2-like dopamine receptors mediate the response to amphetamine in a mouse model of ADHD. Neurobiol. Dis. 2007, 26:201-211.
51. Fan X., Xu M., Hess E.J. D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD. Neurobiol. Dis. 2010, 37:228-236.
52. Fanous A.H., van den Oord E.J., Riley B.P., Aggen S.H., Neale M.C., O'Neill F.A., et al. Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am. J. Psychiatr. 2005, 162:1824-1832.
53. Fazzari P., Paternain A.V., Valiente M., Pla R., Lujan R., Lloyd K., et al. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature 2010, 464:1376-1380.
54. Feng Y.Q., Zhou Z.Y., He X., Wang H., Guo X.L., Hao C.J., et al. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr. Res. 2008, 106:218-228.
55. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rössler A., Schultze-Lutter F., et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
56. Futamura T., Toyooka K., Iritani S., Niizato K., Nakamura R., Tsuchiya K., et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol. Psychiatry 2002, 7:673-682.
57. Gainetdinov R.R., Jones S.R., Caron M.G. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry 1999, 46:303-311.
58. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001, 24:527-533.
59. Ghiani C.A., Dell'Angelica E.C. Dysbindin-containing complexes and their proposed functions in brain: from zero to (too) many in a decade. ASN Neuro. 2011, 3. 10.1042/AN20110010.
60. Ginovart N., Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb. Exp. Pharmacol. 2012, 212:27-52.
61. Glickstein S.B., Hof P.R., Schmauss C. Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. J. Neurosci. 2002, 22:5619-5629.
62. Gokhale A., Larimore J., Werner E., So L., Moreno-De-Luca A., Lese-Martin C., et al. Quantitative proteomic and genetic analyses of the schizophrenia susceptibility factor dysbindin identify novel roles of the biogenesis of lysosome-related organelles complex 1. J. Neurosci. 2012, 32:3697-3711.
63. Goldberg X., Fatjó-Vilas M., Alemany S., Nenadic I., Gastó C., et al. Gene-environment interaction on cognition: a twin study of childhood maltreatment and COMT variability. J. Psychiatr. Res. 2013, 47:989-994.
64. Goldman-Rakic P.S. The cortical dopamine system: role in memory and cognition. Adv. Pharmacol. 1998, 42:707-711.
65. Gray L., Hannan A.J. Dissecting cause and effect in the pathogenesis of psychiatric disorders: genes, environment and behaviour. Curr. Mol. Med. 2007, 7:470-478.
66. Grizenko N., Fortier M.E., Zadorozny C., Thakur G., Schmitz N., Duval R., et al. Maternal stress during pregnancy, ADHD symptomatology in children and genotype: gene-environment interaction. J. Can. Acad. Child Adolesc. Psychiatry 2012, 21:9-15.
67. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 2006, 12:824-828.
68. Haluk D.M., Floresco S.B. Ventral striatal dopamine modulation of different forms of behavioral flexibility. Neuropsychopharmacology 2009, 34:2041-2052.
69. Haque F.N., Lipina T.V., Roder J.C., Wong A.H. Social defeat interacts with Disc1 mutations in the mouse to affect behavior. Behav. Brain Res. 2012, 233:337-344.
70. Harrison P.J., Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry 2006, 60:132-140.
71. Hashimoto R., Straub R.E., Weickert C.S., Hyde T.M., Kleinman J.E., Weinberger D.R. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol. Psychiatry 2004, 9:299-307.
72. Hashimoto R., Noguchi H., Hori H., Ohi K., Yasuda Y., Takeda M., et al. Association between the dysbindin gene (DTNBP1) and cognitive functions in Japanese subjects. Psychiatry Clin. Neurosci. 2009, 63:550-556.
73. Hattori S., Murotani T., Matsuzaki S., Ishizuka T., Kumamoto N., Takeda M., et al. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem. Biophys. Res. Commun. 2008, 373:298-302.
74. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr. Res. 2006, 86:138-146.
75. Howes O.D., Murray R.M. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet 2013, 10.1016/S0140-6736(13)62036-X.
76. Howes O.D., Bose S.K., Turkheimer F., Valli I., Egerton A., Valmaggia L.R., Murray R.M., McGuire P. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging. Am. J. Psychiatr. 2011, 168:13117.
77. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 2012, 69:776-786.
78. Ibi D., Nagai T., Kitahara Y., Mizoguchi H., Koike H., Shiraki A., et al. Neonatal polyI:C treatment in mice results in schizophrenia-like behavioral and neurochemical abnormalities in adulthood. Neurosci. Res. 2009, 64:297-305.
79. Iizuka Y., Sei Y., Weinberger D.R., Straub R.E. Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J. Neurosci. 2007, 27:12390-12395.
80. Jaaro-Peled H., Niwa M., Foss C.A., Murai R., de Los Reyes S., Kamiya A., et al. Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging. Hum. Mol. Genet. 2013, 22:1574-1580.
81. Janssen M.J., Leiva-Salcedo E., Buonanno A. Neuregulin directly decreases voltage-gated sodium current in hippocampal ErbB4-expressing interneurons. J. Neurosci. 2012, 32:13889-13895.
82. Jeans A., Malins R., Padamsey Z., Reinhart M., Emptage N. Increased expression of dysbindin-1A leads to a selective deficit in NMDA receptor signaling in the hippocampus. Neuropharmacology 2011, 61:1345-1353.
83. Ji Y., Yang F., Papaleo F., Wang H.X., Gao W.J., Weinberger D.R., et al. Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19593-19598.
84. Jia J.M., Zhao J., Hu Z., Lindberg D., Li Z. Age-dependent regulation of synaptic connections by dopamine D2 receptors. Nat. Neurosci. 2013, 16:1627-1636.
85. Jones C.A., Watson D.J., Fone K.C. Animal models of schizophrenia. Br. J. Pharmacol. 2011, 164:1162-1194.
86. Kadkhodaei B., Ito T., Joodmardi E., Mattsson B., Rouillard C., Carta M., et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 2009, 29:15923-15932.
87. Kannan G., Sawa A., Pletnikov M.V. Mouse models of gene-environment interactions in schizophrenia. Neurobiol. Dis. 2013, 57:5-11.
88. Karl T., Duffy L., Scimone A., Harvey R.P., Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav. 2007, 6:677-687.
89. Karl T., Burne T.H., Van den Buuse M., Chesworth R. Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?. Behav. Brain Res. 2011, 223:336-341.
90. Karlsgodt K.H., Robleto K., Trantham-Davidson H., Jairl C., Cannon T.D., Lavin A., et al. Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol. Psychiatry 2011, 69:28-34.
91. Kas M.J., Kahn R.S., Collier D.A., Waddington J.L., Ekelund J., Porteous D.J., et al. Translational neuroscience of schizophrenia: seeking a meeting of minds between mouse and man. Sci. Transl. Med. 2011, 3:102mr3.
92. Kato T., Kasai A., Mizuno M., Fengyi L., Shintani N., Maeda S., et al. Phenotypic characterization of transgenic mice overexpressing neuregulin-1. PLoS One 2010, 5:e14185.
93. Kato T., Abe Y., Sotoyama H., Kakita A., Kominami R., Hirokawa S., et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol. Psychiatry 2011, 16:307-320.
94. Keck T.M., Suchland K.L., Jimenez C.C., Grandy D.K. Dopamine D4 receptor deficiency in mice alters behavioral responses to anxiogenic stimuli and the psychostimulant methylphenidate. Pharmacol. Biochem. Behav. 2013, 103:831-841.
95. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 1999, 25:201-222.
96. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
97. Kerber G., Streif R., Schwaiger F., Kreutzberg G., Hager G. Neuregulin-1 isoforms are differentially expressed in the intact and regenerating adult rat nervous system. J. Mol. Neurosci. 2003, 21:149-165.
98. Keshavan M.S., Nasrallah H.A., Tandon R. Schizophrenia, "just the facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr. Res. 2011, 127:3-13.
99. Kuepper R., Skinbjerg M., Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb. Exp. Pharmacol. 2012, 212:1-26.
100. Kumamoto N., Matsuzaki S., Inoue K., Hattori T., Shimizu S., Hashimoto R., et al. Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin. Biochem. Biophys. Res. Commun. 2006, 345:904-909.
101. Kwon O.B., Longart M., Vullhorst D., Hoffman D.A., Buonanno A. Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses. J. Neurosci. 2005, 25:9378-9383.
102. Kwon O.B., Paredes D., Gonzalez C.M., Neddens J., Hernandez L., Vullhorst D., et al. Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15587-15592.
103. Law A.J., Weickert C.S., Hyde T.M., Kleinman J.E., Harrison P.J. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience 2004, 127:125-136.
104. Law A.J., Lipska B.K., Weickert C.S., Hyde T.M., Straub R.E., Hashimoto R., et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 50 SNPs associated with the disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6747-6752.
105. Law A.J., Kleinman J.E., Weinberger D.R., Weickert C.S. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum. Mol. Genet. 2007, 16:129-141.
106. Lehner T. The genes in the major histocompatibility complex as risk factors for schizophrenia: de omnibus dubitandum. Biol. Psychiatry 2012, 72:615-616.
107. Le Moine C., Gaspar P. Subpopulations of cortical GABAergic interneurons differ by their expression of D1 and D2 dopamine receptor subtypes. Brain Res. Mol. Brain Res. 1998, 58:231-236.
108. Leo D., Gainetdinov R.R. Transgenic mouse models for ADHD. Cell Tissue Res. 2013, 354:259-271.
109. Li W., Zhang Q., Oiso N., Novak E.K., Gautam R., O'Brien E.P., et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat. Genet. 2003, 35:84-89.
110. Lipina T.V., Niwa M., Jaaro-Peled H., Fletcher P.J., Seeman P., Sawa A., et al. Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia. Genes Brain Behav. 2010, 9:777-789.
111. Lobo M.K., Zaman S., Damez-Werno D.M., Koo J.W., Bagot R.C., DiNieri J.A., et al. δFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. J. Neurosci. 2013, 33:18381-18395.
112. Lubow R.E., Moore A.U. Latent inhibition: the effect of nonreinforced pre-exposure to the conditional stimulus. J. Comp. Physiol. Psychol. 1959, 52:415-419.
113. Luciano M., Miyajima F., Lind P.A., Bates T.C., Horan M., Harris S.E., et al. Variation in the dysbindin gene and normal cognitive function in three independent population samples. Genes Brain Behav. 2009, 8:218-227.
114. Markov V., Krug A., Krach S., Whitney C., Eggermann T., Zerres K., et al. Genetic variation in schizophrenia-risk-gene dysbindin 1 modulates brain activation in anterior cingulate cortex and right temporal gyrus during language production in healthy individuals. Neuroimage 2009, 47:2016-2022.
115. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
116. Mier D., Kirsch P., Meyer-Lindenberg A. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry 2010, 15:918-927.
117. Minzenberg M.J., Poole J.H., Benton C., Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am. J. Psychiatr. 2004, 161:116-124.
118. Mizuno M., Kawamura H., Takei N., Nawa H. The anthraquinone derivative emodin ameliorates neurobehavioral deficits of a rodent model for schizophrenia. J. Neural Transm. 2008, 115:521-530.
119. Mizuno M., Iwakura Y., Shibuya M., Zheng Y., Eda T., Kato T., et al. Antipsychotic potential of quinazoline ErbB1 inhibitors in a schizophrenia model established with neonatal hippocampal lesioning. J. Pharmacol. Sci. 2010, 114:320-331.
120. Mizuno M., Kawamura H., Ishizuka Y., Sotoyama H., Nawa H. The anthraquinone derivative emodin attenuates methamphetamine-induced hyperlocomotion and startle response in rats. Pharmacol. Biochem. Behav. 2010, 97:392-398.
121. Mizuno M., Sotoyama H., Namba H., Shibuya M., Eda T., Wang R., et al. ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions. Transl. Psychiatry 2013, 2:e252.
122. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
123. Mouri A., Nagai T., Ibi D., Yamada K. Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. Neurobiol. Dis. 2013, 53:61-74.
124. Mullin A.P., Gokhale A., Moreno-De Luca A., Sanyal S., Waddington J.L., Faundez V. Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes. Transl. Psychiatry 2013, 3:e329.
125. Munafo M.R., Attwood A.S., Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr. Bull. 2008, 34:9-12.
126. Murotani T., Ishizuka T., Hattori S., Hashimoto R., Matsuzaki S., Yamatodani A. High dopamine turnover in the brains of Sandy mice. Neurosci. Lett. 2007, 421:47-51.
127. Nagai T., Kitahara Y., Shiraki A., Hikita T., Taya S., Kaibuchi K., et al. Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: an in vivo microdialysis study. Neurosci. Lett. 2010, 470:134-138.
128. Newell K.A., Karl T., Huang X.F. A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice. Neuroscience 2013, 248:670-680.
129. Ohara A., Kasahara Y., Yamamoto H., Hata H., Kobayashi H., Numachi Y., et al. Exclusive expression of VMAT2 in noradrenergic neurons increases viability of homozygous VMAT2 knockout mice. Biochem. Biophys. Res. Commun. 2013, 432:526-532.
130. Oliver P.L., Davies K.E. Interaction between environmental and genetic factors modulates schizophrenic endophenotypes in the Snap-25 mouse mutant blind-drunk. Hum. Mol. Genet. 2009, 18:4576-4589.
131. O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Harvey R.P., Tighe O., Croke D.T., et al. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport 2006, 17:79-83.
132. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 2007, 147:18-27.
133. O'Tuathaigh C.M., Hryniewiecka M., Behan A., Tighe O., Coughlan C., Desbonnet L., et al. Chronic adolescent exposure to Delta-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 2010, 35:2262-2273.
134. O'Tuathaigh C.M., Clarke G., Walsh J., Desbonnet L., Petit E., O'Leary C., et al. Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int. J. Neuropsychopharmacol. 2012, 15:1331-1342.
135. O'Tuathaigh C.M., Desbonnet L., Waddington J.L. Mutant mouse models in evaluating novel approaches to antipsychotic treatment. Handb. Exp. Pharmacol. 2012, 213:113-145.
136. O'Tuathaigh C.M., Desbonnet L., Perez-Branguli F., Petit E., O'Leary C., Clarke N., et al. Mice with simultaneous disruption of DISC1 and NRG1 genes exhibit phenotypes related to schizophrenia 2012, Society for Neuroscience, New Orleans, LA, Program No. 663.19, Online.
137. Owen M.J., Craddock N., O'Donovan M.C. Suggestion of roles for both the common and rare risk variants in genome-wide studies of schizophrenia. Arch. Gen. Psychiatry 2010, 67:667-673.
138. Pan B., Huang X.F., Deng C. Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:924-930.
139. Papaleo F., Weinberger D.R. Dysbindin and Schizophrenia: it's dopamine and glutamate all over again. Biol. Psychiatry 2011, 69:2-4.
140. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J. Neurosci. 2008, 28:8709-8723.
141. Papaleo F., Erickson L., Liu G., Chen J., Weinberger D.R. Effects of sex and COMT genotype on environmentally modulated cognitive control in mice. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20160-20165.
142. Papaleo F., Lipska B.K., Weinberger D.R. Mouse models of genetic effects on cognition: relevance to schizophrenia. Neuropharmacology 2012, 62:1204-1220.
143. Papaleo F., Yang F., Garcia S., Chen J., Lu B., Crawley J.N., et al. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol. Psychiatry 2012, 17:85-98.
144. Papaleo F., Burdick M.C., Callicott J.H., Weinberger D.R. Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. Mol. Psychiatry 2014, 19:311-316. 10.1038/mp.2013.133.
145. Parlapani E., Schmitt A., Wirths O., Bauer M., Sommer C., Rueb U., et al. Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World J. Biol. Psychiatry 2010, 11:243-250.
146. Pecina S., Cagniard B., Berridge K.C., Aldridge J.W., Zhuang X. Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J. Neurosci. 2003, 23:9395-9402.
147. Petit E., O'Tuathaigh C., Kirby B., Desbonnet L., Niahm C., Tighe O., et al. Phenotypic studies on a novel mutant with targeted deletion of the schizophrenia risk gene Dtnbp1 (dysbindin). FENS Abstract 2012, 6:124.12.
148. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioural abnormalities reminiscent of schizophrenia. Mol. Psychiatry 2008, 13:173-186.
149. Pogorelov V.M., Nomura J., Kim J., Kannan G., Ayhan Y., Yang C., et al. Mutant DISC1 affects methamphetamine-induced sensitization and conditioned place preference. Neuropharmacology 2012, 62:1242-1251.
150. Ralph-Williams R.J., Lehmann-Masten V., Otero-Corchon V., Low M.J., Geyer M.A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J. Neurosci. 2002, 22:9604-9611.
151. Rao A., Sorkin A., Zahniser N.R. Mice expressing markedly reduced striatal dopamine transporters exhibit increased locomotor activity, dopamine uptake turnover rate, and cocaine responsiveness. Synapse 2013, 67:668-677.
152. Rhein M., Muschler M.R., Krauss J.K., Bleich S., Frieling H., Schwabe K. Hypomethylation of neuregulin in rats selectively bred for reduced sensorimotor gating. Schizophr. Res. 2013, 150:262-265.
153. Rimer M., Barrett D.W., Maldonado M.A., Vock V.M., Gonzalez-Lima F. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport 2005, 16:271-275.
154. Robbins T.W., Kousta S. Uncovering the genetic underpinnings of cognition. Trends Cogn. Sci. 2011, 15:375-377.
155. Robinson S., Rainwater A.J., Hnasko T.S., Palmiter R.D. Viral restoration of dopamine signaling to the dorsal striatum restores instrumental conditioning to dopamine-deficient mice. Psychopharmacology 2007, 191:567-578.
156. Rojas P., Joodmardi E., Hong Y., Perlmann T., Ogren S.O. Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol. Psychiatry 2007, 12:756-766.
157. Saggu S., Cannon T.D., Jentsch J.D., Lavin A. Potential molecular mechanisms for decreased synaptic glutamate release in dysbindin-1 mutant mice. Schizophr. Res. 2013, 146:254-263.
158. Sakurai H., Bies R.R., Stroup S.T., Keefe R.S., Rajji T.K., Suzuki T., et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr. Bull. 2013, 39:564-574.
159. Salahpour A., Ramsey A.J., Medvedev I.O., Kile B., Sotnikova T.D., Holmstrand E., et al. Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4405-4410.
160. Santana N., Mengod G., Artigas F. Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 2009, 19:849-860.
161. Scheggia D., Sannino S., Scattoni M.L., Papaleo F. COMT as a drug target for cognitive functions and dysfunctions. CNS Neurol. Disord. Drug Targets 2012, 11:209-221.
162. Schwab S.G., Knapp M., Mondabon S., Hallmayer J., Borrmann-Hassenbach M., Albus M., et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 2003, 72:185-190.
163. Seamans J.K., Gorelova N., Durstewitz D., Yang C.R. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J. Neurosci. 2001, 21:3628-3638.
164. Seeman P. Schizophrenia and dopamine receptors. Eur. Neuropsychopharmacol. 2013, 23:999-1009.
165. Seeman P., Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7673-7675.
166. Shao L., Shuai Y., Wang J., Feng S., Lu B., Li Z., et al. Schizophrenia susceptibility gene dysbindin regulates glutamatergic and dopaminergic functions via distinctive mechanisms in Drosophila. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:18831-18836.
167. Shibuya M., Komi E., Wang R., Kato T., Watanabe Y., Sakai M., et al. Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. J. Neural Transm. 2010, 117:887-895.
168. Simpson E.H., Kellendonk C., Ward R.D., Richards V., Lipatova O., Fairhurst S., et al. Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia. Biol. Psychiatry 2011, 69:928-935.
169. Smardencas A., Rizkalla K., Kim H.A., Massalas J., O'Leary C., Ehrlich M.E., et al. Phenotyping dividing cells in mouse models of neurodegenerative basal ganglia diseases. BMC Neurosci. 2013, 14:111.
170. Snyder S.H. What dopamine does in the brain. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:18869-18871.
171. Sotoyama H., Zheng Y., Iwakura Y., Mizuno M., Aizawa M., Shcherbakova K., et al. Pallidal hyperdopaminergic innervation underlying D2 receptor-dependent behavioral deficits in the schizophrenia animal model established by EGF. PLoS One 2011, 6:e25831.
172. Starcevic M., Dell'Angelica E.C. Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1). J. Biol. Chem. 2004, 279:28393-28401.
173. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 2002, 71:877-892.
174. Straub R.E., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., Harris-Kerr C., et al. Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. Mol. Psychiatry 2002, 7:542-559.
175. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 2008, 199:331-388.
176. Swerdlow N.R., Shilling P.D., Breier M., Trim R.S., Light G.A., Marie R.S. Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology 2012, 224:349-362.
177. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:9938-9943.
178. Takao K., Toyama K., Nakanishi K., Hattori S., Takamura H., Takeda M., et al. Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Mol. Brain 2008, 1:11.
179. Talbot K. The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. Prog. Brain Res. 2009, 179:87-94.
180. Talbot K., Eidem W.L., Tinsley C.L., Benson M.A., Thompson E.W., Smith R.J. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J. Clin. Investig. 2004, 113:1353-1363.
181. Talbot K., Cho D.S., Ong W.Y., Benson M.A., Han L.Y., Kazi H.A. Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. Hum. Mol. Genet. 2006, 15:3041-3054.
182. Talbot K., Ong W.Y., Blake D.J., Tang J., Louneva N., Carlson G.C., et al. Dysbindin-1 and its protein family. Handbook of Neurochemistry and Molecular Neurobiology 2009, vol. 27:107-241. Springer Science, New York, NY. D.C. Javitt, J. Kantrowitz (Eds.).
183. Talbot K., Louneva N., Cohen J.W., Kazi H., Blake D.J., Arnold S.E. Synaptic dysbindin-1 reductions in schizophrenia occur in an isoform-specific manner indicating their subsynaptic location. PLoS One 2011, 6:e168886.
184. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr. Res. 2008, 102:1-18.
185. Tang J., LeGros R.P., Louneva N., Yeh L., Cohen J.W., Hahn C.G., et al. Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum. Mol. Genet. 2009, 18:3851-3863.
186. Tang T.T., Yang F., Chen B.S., Lu Y., Ji Y., Roche K.W., et al. Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface expression. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21395-21400.
187. Thimm M., Krug A., Kellermann T., Markov V., Krach S., et al. The effects of a DTNBP1 gene variant on attention networks: an fMRI study. Behav. Brain Funct. 2010, 6:54.
188. Thuret S., Alavian K.N., Gassmann M., Lloyd C.K., Smits S.M., Smidt M.P., et al. The neuregulin receptor, ErbB4, is not required for normal development and adult maintenance of the substantia nigra pars compacta. J. Neurochem. 2004, 91:1302-1311.
189. Tomiyama K., Drago J., Waddington J.L., Koshikawa N. Constitutive and conditional mutant mouse models for understanding dopaminergic regulation of orofacial movements: emerging insights and challenges. J. Pharmacol. Sci. 2012, 119:297-301.
190. Trifilieff P., Feng B., Urizar E., Winiger V., Ward R.D., Taylor K.M., et al. Increasing D2 receptor expression in the adult nucleus accumbens enhances motivation. Mol. Psychiatry 2013, 18:1025-1033.
191. Trinh J.V., Nehrenberg D.L., Jacobsen J.P., Caron M.G., Wetsel W.C. Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 2003, 118:297-310.
192. Uchida H., Rajji T.K., Mulsant B.H., Kapur S., Pollock B.G., Graff-Guerrero A., et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J. Clin. Psychopharmacol. 2009, 29:571-575.
193. Van Den Bogaert A., Schumacher J., Schulze T.G., Otte A.C., Ohlraun S., Kovalenko S., et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am. J. Hum. Genet. 2003, 73:1438-1443.
194. van den Buuse M., Wischhof L., Xi Lee R., Martin S., Karl T. Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int. J. Neuropsychopharmacol. 2009, 12:1383-1393.
195. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
196. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
197. Vialou V., Robison A.J., Laplant Q.C., Covington H.E., Dietz D.M., Ohnishi Y.N., et al. DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat. Neurosci. 2010, 13:745-752.
198. Vijayraghavan S., Wang M., Birnbaum S.G., Williams G.V., Arnsten A.F. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 2007, 10:376-384.
199. Vuillermot S., Weber L., Feldon J., Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J. Neurosci. 2010, 30:1270-1287.
200. Vuillermot S., Joodmardi E., Perlmann T., Ögren S.O., Feldon J., Meyer U. Prenatal immune activation interacts with genetic Nurr1 deficiency in the development of attentional impairments. J. Neurosci. 2012, 32:436-451.
201. Vullhorst D., Neddens J., Karavanova I., Tricoire L., Petralia R.S., McBain C.J., et al. Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. J. Neurosci. 2009, 29:12255-12264.
202. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 2005, 181:611-638.
203. Waddington J.L., O'Tuathaigh C.M., Remington G.J. The pharmacology and neuroscience of antipsychotic drugs. Schizophrenia 2011, 485-514. Wiley-Blackwell, Oxford. third ed. D.R. Weinberger, P.J. Harrison (Eds.).
204. Waddington J.L., Hennessy R.J., O'Tuathaigh C.M.P., Owoeye O., Russell V. Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redux. The Origins of Schizophrenia 2012, 3-21. Columbia University Press, New York, NY. A.S. Brown, P.H. Patterson (Eds.).
205. Walker R.M., Christoforou A., Thomson P.A., McGhee K.A., Maclean A., Muhleisen T.W., et al. Association analysis of neuregulin 1 candidate regions in schizophrenia and bipolar disorder. Neurosci. Lett. 2010, 478:9-13.
206. Walsh J., Tighe O., Lai D., Harvey R., Karayiorgou M., Gogos J.A., Waddington J.L., et al. Disruption of thermal nociceptive behaviour in mice mutant for the schizophrenia-associated genes NRG1, COMT and DISC1. Brain Res. 2010, 1348:114-119.
207. Wang Y.M., Gainetdinov R.R., Fumagalli F., Xu F., Jones S.R., Bock C.B., et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997, 19:1285-1296.
208. Wang M., Vijayraghavan S., Goldman-Rakic P.S. Selective D2 receptor actions on the functional circuitry of working memory. Science 2004, 303:853-856.
209. Wang X.D., Su Y.A., Guo C.M., Yang Y., Si T.M. Chronic antipsychotic drug administration alters the expression of neuregulin 1b, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. Int. J. Neuropsychopharmacol. 2008, 11:553-556.
210. Weickert C.S., Straub R.E., McClintock B.W., Matsumoto M., Hashimoto R., Hyde T.M., et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry 2004, 61:544-555.
211. Weickert C.S., Rothmond D.A., Hyde T.M., Kleinman J.E., Straub R.E. Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizophr. Res. 2008, 98:105-110.
212. Weiner I., Arad M. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav. Brain Res. 2009, 204:369-386.
213. Wen L., Lu Y.S., Zhu X.H., Li X.M., Woo R.S., Chen Y.J., et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1211-1216.
214. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995, 376:572-575.
215. Winterer G., Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004, 27:683-690.
216. Wirth C., Schubert F., Lautenschlager M., Bruhl R., Klar A., Majic T., et al. DTNBP1 (dysbindin) gene variants: in vivo evidence for effects on hippocampal glutamate status. Curr. Pharm. Biotechnol. 2012, 13:1513-1521.
217. Wolf C., Jackson M.C., Kissling C., Thome J., Linden D.E. Dysbindin-1 genotype effects on emotional working memory. Mol. Psychiatry 2011, 16:145-155.
218. Yamashita M., Sakakibara Y., Hall F.S., Numachi Y., Yoshida S., Kobayashi H., et al. Impaired cliff avoidance reaction in dopamine transporter knockout mice. Psychopharmacology 2013, 227:741-749.
219. Yizhar O., Fenno L.E., Prigge M., Schneider F., Davidson T.J., O'Shea D.J., et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011, 477:171-178.
220. Yurek D.M., Zhang L., Fletcher-Turner A., Seroogy K.B. Supranigral injection of neuregulin1-beta induces striatal dopamine overflow. Brain Res. 2004, 1028:116-119.
221. Zhang Y., Bertolino A., Fazio L., Blasi G., Rampino A., Romano R., et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20552-20557.
222. Zhang H.X., Zhao J.P., Lv L.X., Li W.Q., Xu L., Ouyang X., et al. Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neurosci. Lett. 2008, 438:1-5.
223. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1982-1987.
224. Zinkstok J.R., de Wilde O., van Amelsvoort T.A., Tanck M.W., Baas F., Linszen D.H. Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. Behav. Brain Funct. 2007, 3:19.
225. Zohsel K., Buchmann A.F., Blomeyer D., Hohm E., Schmidt M.H., Esser G., et al. Mothers' prenatal stress and their children's antisocial outcomes-a moderating role for the Dopamine D4 Receptor (DRD4) gene. J. Child Psychol. Psychiatry 2014, 55:69-76.